MEF2C and non-small cell lung carcinoma: MEF2C, previously implicated in hematopoietic malignancies and increasingly recognized in solid tumors, may act downstream or in parallel with STAT3, forming a signaling axis that contributes to NSCLC progression through modulation of vascular and immune niches.